EI
CSTL icon

EAM Investors’s Castle Biosciences CSTL Stock Holding History

EAM Investors’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-74,138
Closed -$2.88M – 296
2025
Q4 		$2.88M Buy
+74,138
New +$2.39M 0.32% 148
2021
Q1 		– Sell
-26,357
Closed -$1.77M – 363
2020
Q4 		$1.77M Sell
26,357
-38,278
-59% -$2.07M 0.29% 161
2020
Q3 		$3.33M Sell
64,635
-13,966
-18% -$621K 0.79% 13
2020
Q2 		$2.96M Sell
78,601
-11,562
-13% -$395K 0.65% 27
2020
Q1 		$2.69M Buy
90,163
+24,751
+38% +$747K 0.83% 20
2019
Q4 		$2.25M Buy
65,412
+31,407
+92% +$768K 0.49% 64
2019
Q3 		$615K Buy
+34,005
New +$754K 0.16% 218

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM Investors's CSTL Position: Q1 2026 in Review

EAM Investors sold out of Castle Biosciences (CSTL) in Q1 2026, closing a stake of 74,138 shares — an estimated $2.88M sold.

EAM Investors first reported a position in CSTL in Q3 2019 and held it in 7 quarters. The position peaked at $3.33M in Q3 2020. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • EAM Investors reported no remaining Castle Biosciences position as of Q1 2026 after selling out during the quarter.
  • EAM Investors sold 74,138 Castle Biosciences shares in Q1 2026, an estimated $2.88M.
  • EAM Investors first reported a position in Castle Biosciences in Q3 2019 and held it in 7 quarters.
  • EAM Investors's Castle Biosciences position peaked at $3.33M in Q3 2020.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.